Effect of collagen turnover and matrix metalloproteinase activity on healing of venous leg ulcers

British Journal of Surgery

Volumn 95, Issue 3, 2008, Pages 319-325

  Meyer, F J ^a   Burnand, K G ^a   Abisi, S ^a   TeKoppele, J M ^b   Van Els, B ^b   Smith, A ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TYPE 3; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE III N TERMINAL PEPTIDE; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; LEG ULCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; SKIN BIOPSY; WOUND HEALING; AGED; COMPARATIVE STUDY; ENZYMOLOGY; FEMALE; MALE; METABOLISM; PHYSIOLOGY; SKIN; VARICOSIS;

AGED; COLLAGEN; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; PEPTIDE FRAGMENTS; PROCOLLAGEN; SKIN; VARICOSE ULCER; WOUND HEALING;

EID: 40749088928     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5946     Document Type: Article

References (34)

1. Baker SR, Stacey MC, Jopp-McKay AG, Hoskin SE, Thompson PJ. Epidemiology of chronic venous ulcers. Br J Surg 1991; 78: 864-867.
2. Callam MJ, Ruckley CV, Harper DR, Dale JJ. Chronic ulceration of the leg: extent of the problem and provision of care. Br Med J (Clin Res Ed) 1985; 290: 1855-1856.
3. Nelzen O, Bergqvist D, Lindhagen A. The prevalence of chronic lower-limb ulceration has been underestimated: results of a validated population questionnaire. Br J Surg 1996; 83: 255-258.
4. Ruckley CV. Socioeconomic impact of chronic venous insufficiency and leg ulcers. Angiology 1997; 48: 67-69.
5. Marston WA, Carlin RE, Passman MA, Farber MA, Keagy BA. Healing rates and cost efficacy of outpatient compression treatment for leg ulcers associated with venous insufficiency. J Vasc Surg 1999; 30: 491-498.
6. Meyer FJ, Burnand KG, Lagattolla NR, Eastham D. Randomized clinical trial comparing the efficacy of two bandaging regimens in the treatment of venous leg ulcers. Br J Surg 2002; 89: 40-44.
7. Meyer FJ, McGuinness CL, Lagattolla NR, Eastham D, Burnand KG. Randomized clinical trial of three-layer paste and four-layer bandages for venous leg ulcers. Br J Surg 2003; 90: 934-940.
8. Cullum N, Nelson EA, Fletcher AW, Sheldon 'FA. Compression for venous leg ulcers. Cochrane Database Syst Rev 2000; (2)CD000265.
9. Oien RF, Hakansson A, Hansen BU, Bjellerup M. Pinch grafting of chronic leg ulcers in primary care: fourteen years' experience. Acta Derm Venereol 2002; 82: 275-278.
10. Schmeller W, Gaber Y. Surgical removal of ulcer and lipodermatosclcrosis followed by split-skin grafting (shave therapy) yields good long-term results in 'non-healing' venous leg ulcers. Acta Derm Venereol 2000; 80: 267-271.
11. Jones JE, Nelson EA. Skin grafting for venous leg ulcers. Cochrane Database Syst Rev 2005; (1)CD001737.
12. Mendez MV, Raffetto JD, Phillips T, Menzoian JO, Park HY. The proliferative capacity of neonatal skin fibroblasts is reduced after exposure to venous ulcer wound fluid: a potential mechanism for senescence in venous ulcers. J Vasc Surg 1999; 30: 734-743.
13. Hasan A, Murata H, Falabella A, Ochoa S, Zhou L, Badiavas E et al. Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1. J Dermatol Sci 1997; 16: 59-66.
14. Herrick SE, Ireland GW, Simon D, McCollum CN, Ferguson MW. Venous ulcer fibroblasts compared with normal fibroblasts show differences in collagen but not fibronectin production under both normal and hypoxic conditions. J Invest Dermatol 1996; 106: 187-193.
15. Stanley AC, Fernandez NN, Lounsbury KM, Corrow K, Osier T, Healey C et al. Pressure-induced cellular senescence: a mechanism linking venous hypertension to venous ulcers. J Surg Res 2005; 124: 112-117.
16. Fleischmajer R, Timpl R, Tuderman L, Raisher L, Wiestner M, Perlish JS et al. Ultrastrucrural identification of extension aminopropeptides of type I and III collagens in human skin. Proc Natl Acad Sci U S A 1981; 78: 7360-7364.
17. Bank RA, Krikken M, Beekman B, Stoop R, Maroudas A, Lafeber FP et al. A simplified measurement of degraded collagen in tissues: application in healthy, fibrillated and osteoarthritic cartilage. Matrix Biol 1997; 16: 233-243.
18. Herouy Y, May AE, Pornschlegel G, Stetter C, Grenz H, Preissner KT et al. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: implications for venous ulcer formation. J Invest Dermatol 1998; 111: 822-827.
19. Norgauer J, Hildenbrand T, Idzko M, Panther E, Bandemir E, Hartmann M et al. Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol 2002; 147: 1180-1186.
20. Saito S, Trovato MJ, You R, Lal BK, Fasehun F, Padberg FT Jr et al. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic-venous insufficiency. J Vasc Surg 2001; 34: 930-938.
21. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F et al. Analysis of the acute and chronic-wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7: 442-452.
22. Weckroth M, Vaheri A, Lauharanta J, Sorsa T, Konttinen YT. Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. J Invest Dermatol 1996; 106:1119-1124.
23. Saarialho-Kere UK. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch Dermatol Res 1998; 290(Suppl): S47-S54.
24. Beekman B, Verzijl N, de Roos JA, TeKoppele JM. Matrix degradation by chondrocytes cultured in alginate: IL-1 beta induces proteoglycan degradation and proMMP synthesis but does not result in collagen degradation. Osteoarthritis Cartilage 1998; 6: 330-340.
25. Beekman B, Drijfhout JW, Ronday HK, TeKoppele JM. Fluorogenic MMP activity assay for plasma including MMPs complexed to alpha 2-macroglobulin. Ann N Y Acad Sci 1999; 878: 150-158.
26. Beekman B, Drijfhout JW, Bloemhoff W, Ronday HK, Tak PP, TeKoppele JM. Convenient fluorometric assay for matrix metalloproteinase activity and its application in biological media. FEBS Lett 1996; 390: 221-225.
27. Toy LW. Matrix metalloproteinases: their function in tissue repair. J Wound Care 2005; 14: 20-22.
28. Woolley DE. Collagenolytic mechanisms in tumor cell invasion. Cancer Metastasis Rev 1984; 3: 361-372.
29. Wilhelm SM, Collier IE, Kronberger A, Eisen A2, Marmer BL, Grant GA et al. Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells. Proc Natl Acad Sci U S A 1987; 84: 6725-6729.
30. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J 1987; 248: 265-268.
31. Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry 1990; 29: 10261-10270.
32. Knauper V, Wilhelm SM, Seperack PK, DeClerck YA, Langley KE, Osthues A et al. Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem J 1993; 295: 581-586.
33. Fini ME, Parks WC, Rinehart WB, Girard MT, Matsubara M, Cook JR et al. Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury. Am J Pathol 1996; 149: 1287-1302.
34. Bullard KM, Lund L, Mudgett JS, Mellin TN, Hunt TK, Murphy B et al. Impaired wound contraction in stromelysin-1-deficient mice. Ann Surg 1999; 230: 260-265.